Days after US regulators granted a swift review for Jardiance for another chronic heart failure indication, Boehringer Ingelheim GmbH and Eli Lilly and Company have presented data showing that their blockbuster SGLT2 inhibitor could benefit adults hospitalized with acute heart failure.
The partners have presented data from the 530-patient Phase III EMPULSE trial at the American Heart Association meeting which revealed...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
